CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today

CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today

Virtual Medical Event Available from the Convenience of a Computer www.CardioCareLive.com takes place entirely online Tuesday March 3 and Wednesday March 4 from 9:30 AM to 8:00 PM Eastern. Patch Adams, MD, the real physician behind the movie starring Robin Williams, is even slated to speak. To register now for free, visit cardioCareLive.com.

Needham, MA (PRWEB) March 3, 2009 -- CardioCareLive (http://www.CardioCareLive.com), the first-ever online-only conference for medical professionals who manage patients with cardiometabolic risk factors, begins today at 9:30 AM Eastern. Cardiologists, endocrinologists, primary care physicians and registered nurses can have their questions addressed live by leading experts in cardiometabolic care from the ease of a PC. This event offers live keynote presentations (http://cardiocarelive.com/en_CA/guest/app-agenda) with Q & A, peer networking and an exhibit floor, entirely online at CardioCareLive.com on Tuesday March 3 and Wednesday March 4 from 9:30 AM to 8:00 PM Eastern.

CardioCareLive features leading cardiovascular experts live via video, such as Louis Aronne, MD; Christie Ballantyne, MD; Roger Blumenthal, MD; Robert Eckel, MD; Peter Libby, MD; Laurie Mosca, MD; Richard Nesto, MD; Clyde Yancy, MD and more. Patch Adams, MD, the real physician behind the movie starring Robin Williams, is even slated to speak.

Acknowledging the busy lives of physicians, CardioCareLive offers continuing education (http://cardiocarelive.com/en_CA/guest/cme) at no cost and completely online, and all presentations will be available on-demand for ninety days after the event concludes. To view a complete list of speakers, agenda, or to register now for free, visit CardioCareLive.com.

About CardioCareLive

CardioCareLive.com, a medical conference which features "Improving Cardiometabolic Patient Outcomes" presented by Johns Hopkins Office of Continuing Medical Education, take place entirely online, enables healthcare practitioners and others interested in understanding and managing cardiometabolic risk factors to learn, connect and interact through powerful Web-based software and services.

CardioCareLive is produced, in cooperation with Johns Hopkins, by PlatformQ whose mission is to connect people, companies, organizations and associations worldwide to meet, interact and learn from leading experts and thought leaders through proven interactive tools at online events.

CardioCareLive and PlatformQ are trademarks of PlatformQ, LLC. All other trademarks or service marks are property of their respective owners.

###

Contact Information Martha Collins

PlatformQ, LLC.

http://www.CardioCareLive.com

(617) 938-6008

Sal Giliberto

PlatformQ, LLC.

http://www.CardioCareLive.com

(617) 938-6006

VisMini 2.0 Carry-On Stereo 3D Projector, Low Cost, No Silver Screen - Available Now from Valley View Tech

VisMini 2.0 Carry-On Stereo 3D Projector, Low Cost, No Silver Screen - Available Now from Valley View Tech

VisMini 2.0 Portable Stereo 3D Projector, from Valley View Tech, cutting-edge technology, lowest-price (US $13,995), highly portable and versatile, passive stereo 3D projector-pair display system - less than one-half the price/weight of competitive systems with NO silver screen needed for display.

Los Gatos, CA (PRWEB) March 3, 2009 -- Valley View Tech, a Silicon Valley-based marketing and sales firm specializing in high-quality, high-tech products for 3D visualization, virtual reality, and immersive 3D, today announced the availability of VisMini 2.0 by Visbox, Inc. VisMini is the value leader in high-quality, truly-portable (fits in an airplane overhead), passive stereoscopic 3D projectors and requires no silver screen -- no more need to carry around an additional 50-100 pounds. The system is ideal for anyone who wants the dramatic impact of stereo 3D and needs to "take stereo 3D on the road."

VisMini 2.0 weighs just 11 pounds, is approximately the size of a three-ream stack of standard paper (11.2" wide x 9" deep x 6.3" high), and is the first truly portable passive stereo 3D solution. The VisMini projector comes with a hardened Pelican™ case, enabling the user to move quickly through airports with convenient carry-on sized baggage that fits in the overhead compartment of most airplanes.

The combined weight of the VisMini Basic with hardened case, glasses, and cables is just 27 pounds. By comparison, other so called "portable" passive stereo 3D projectors cost $35,000 and up, twice the price of the VisMini, and require heavy, cumbersome "silver screens," weighing from 50-to-100+ pounds, too heavy and large to be allowed on board as carry-on luggage. VisMini, the most user friendly 3D stereo projector system available, takes minutes to set up for display on any existing screen or any light-colored wall and projects images that are flicker free for comfortable viewing with passive glasses.

Dr. Carolina Cruz-Neira, Virtual Reality pioneer and co-inventor of the CAVE system, was an early adopter of VisMini. She stated, "I am constantly asked to bring demonstrations of my projects when I travel around the world. VisMini has made it simple and easy to showcase my work outside my lab. VisMini is my personal presentation system for live demonstrations of my 3D work when I am on the road. It is easy carry-on to take with me on planes, quick to set up in most standard conference rooms, and does not require specialized screens or computers."

VisMini is a general-purpose stereo display system that can be used to display a variety of stereo 3D applications and is designed for commercial and academic use -- ranging from medical research and training to geosciences to architecture to entertainment. Any application that supports OpenGL quad-buffered stereo will work with VisMini in stereoscopic 3D mode. This includes applications such as Maya from Autodesk, Discovery Studio from Accelrys, and Second Life in stereoscopic mode. Software designed for active stereo 3D will also project from VisMini.

"The VisMini allows you to walk into any conference room and be ready to present 3D visualizations within a couple of minutes. It is the ideal portable 3D stereo presentation solution," said Paul Rajlich, Vice President, Visbox, Inc. "We are excited to be working with Valley View Tech to help expand the awareness of VisMini and the other Visbox stereo display products to a broader array of both commercial and academic customers around the world."

VisMini 2.0 Basic is available immediately from Valley View Tech for the special introductory price of US$ 13,995. VisMini Basic includes:

•    VisMini projection unit;

•    One premium and four standard pairs of glasses;

•    Video and power cable;

•    Rugged carry-on travel case.

The VisMini 2.0 Basic, including its rugged carry-on case, weighs just 27 pounds and fits in the overhead of most airplanes.

Valley View Tech offers VisMini 2.0 Complete, also available immediately, for the special introductory price of US$ 17,995. VisMini Complete includes:

•    VisMini projection unit;

•    Mobile workstation computer with NVIDIA™ Quadro FX graphics card;

•    DVI to VGA converter;

•    One premium and four standard pairs of glasses;

•    Video and power cables;

•    Rugged, check-in-size travel case to carry all of the above.

The entire VisMini Complete, with case, weighs just 47 pounds and can be taken along as checked baggage.

Both VisMini 2.0 Basic and VisMini 2.0 Complete are calibrated by, and shipped directly from Visbox and carry the Visbox standard warranty.

About Valley View Tech:

Valley View Tech, located in the Santa Cruz Mountains above Silicon Valley, markets, sells, and distributes high-quality, high-tech stereo 3D display products, specifically focused on 3D visualization, immersive 3D, and virtual reality. Valley View Tech represents Visbox' VisMini™ Portable Stereo 3D Projector Displays; Immersive 3D Displays - VisDuo™, VisBox™, and VisCube™; and High Resolution Tiled Displays - VisWall™ and VisWall-LCD™. For more information, please visit: http://www.valleyviewtech.com

Press contact:

Frances Mann-Craik

Addison Marketing

frances (at) addisonmarketing (dot) com

408-868-9577

###

Contact Information Frances Mann-Craik

Valley View Tech

http://www.valleyviewtech.com

408-868-9577

CIRM Completes Briefing Visit to Stemedica Cell Technologies

CIRM Completes Briefing Visit to Stemedica Cell Technologies

Leadership of the California Institute for Regenerative Medicine ("CIRM") completed a two part visit to Stemedica Cell Technologies, Inc. ("Stemedica") to tour its manufacturing facility, R&D lab and corporate headquarters.

San Diego, Calif. (PRWEB) March 2, 2009 -- Leadership of the California Institute for Regenerative Medicine ("CIRM") completed a two part visit to Stemedica Cell Technologies, Inc. ("Stemedica") to tour its manufacturing facility, R&D lab and corporate headquarters.

"I was glad to have the opportunity to visit Stemedica and get to know more about its leadership, plans for the future and to see first hand the assets and potential they represent to the stem cell movement in California", said Dr. Alan Trounson, President of CIRM. "We want to have strong working relationships with all sectors of California's stem cell industry, including for-profit companies like Stemedica."

Prior to Dr. Trounson's visit, Dr. Marie Csete, CIRM's Chief Scientific Officer had the opportunity to visit Stemedica's manufacturing facility and R&D laboratory. "We're delighted to see Stemedica make the effort to secure a clinical grade manufacturing license from the State of California. We believe this capability will aid numerous organizations in California and around the world in their efforts to manufacture stem cell products for clinical application", said Dr. Csete.

"We were pleased to have Dr. Trounson and Dr. Marie Csete visit our facilities and receive a briefing from our leadership", said Dr. Maynard Howe, Stemedica's Vice Chairman & CEO. "We continue to play a pivotal role in the evolution of the stem cell industry in California and believe a supportive working relationship with CIRM is an essential part of this process.

Stuart Lipton, M.D., Ph.D., Scientific Director and Senior Vice President of the Del E. Webb Center for Neuroscience, Aging and Stem Cell Research at the Burnham Institute for Medical Research, San Diego, CA, joined Dr. Trounson during his visit to Stemedica's manufacturing facility. "I was impressed with the progress that Stemedica has made on the licensing process for clinical grade allogeneic stem cell manufacturing and am excited about expanding our research relationship with the Stemedica team. Having a manufacturing resource like this in California will be a great asset to our entire research community. I anticipate that many CIRM-funded stem cell research institutions will take advantage of Stemedica's manufacturing facility that will soon become FDB (Food & Drug Board) cGMP licensed."

Dr. Nikolai Tankovich, Stemedica's President and Chief Medical Officer organized the visits for Dr. Trounson, Dr. Csete and Dr. Lipton. "We're delighted that these outstanding leaders within California's stem cell movement took the time to find out more about Stemedica and our plans to lead this industry from a manufacturing standpoint. We will continue to seek the wise counsel of CIRM in an effort to align our efforts with theirs. In addition, we are expanding our collaborative research efforts with the Burnham Institute for Medical Research and several other California stem cell research institutions", said Dr. Tankovich.

About Stemedica Technologies, Inc.:

Stemedica Cell Technologies Inc. (http://www.stemedica.com (http://www.stemedica.com)) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, California.

About CIRM:

The California Institute for Regenerative Medicine (CIRM) was established in 2005 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. To date, the CIRM governing board has approved 229 research and facility grants totaling more than $614 million, making CIRM the largest source of funding for human stem cell research in the world. For more information, please visit http://www.cirm.ca.gov (http://www.cirm.ca.gov/).

Media Contact for Stemedica: Dave McGuigan at dmcguigan (at) stemedica.com.

# # #

Contact Information Dave McGuigan

Stemedica Cell Technologies Inc

http://www.stemedica.com

+1 858 658 0910

Society of American Gastrointestinal and Endoscopic Surgeons to Present the SAGES 2009 Scientific Session and Postgraduate Courses in April 2009

Society of American Gastrointestinal and Endoscopic Surgeons to Present the SAGES 2009 Scientific Session and Postgraduate Courses in April 2009

The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) will convene its 2009 Scientific Session and Postgraduate Courses in Phoenix, Arizona from April 22-25, 2009. The SAGES Annual Meeting has been the pre-eminent meeting for minimally invasive surgery for the past twenty-eight years. The meeting is expected to draw more than 2,000 surgeons, surgeons-in-training, GI assistants, nurses and other allied health professionals who are interested in minimally invasive surgery and gastrointestinal surgery. The 2009 Program Chair is L. Michael Brunt, MD, from the Washington University School of Medicine in St. Louis, Missouri.

Los Angeles, California (PRWEB) March 1, 2009 -- The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) will convene its 2009 Scientific Session and Postgraduate Courses in Phoenix, Arizona from April 22-25, 2009.

The SAGES Annual Meeting has been the pre-eminent meeting for minimally invasive surgery for the past twenty-eight years. The meeting is expected to draw more than 2,000 surgeons, surgeons-in-training, GI assistants, nurses and other allied health professionals who are interested in minimally invasive surgery and gastrointestinal surgery. The 2009 Program Chair is L. Michael Brunt, MD, from the Washington University School of Medicine in St. Louis, Missouri.

The scientific program has been carefully designed to incorporate many of the scientific and technical advances from the leading experts in the fields of general, gastrointestinal, endoscopic and minimally invasive surgery. The program begins on Wednesday, April 22, 2009 with a variety of half-day postgraduate and hands-on courses on such topics as colorectal, hernia, flexible endoscopy, endolumenal/NOTES®, bariatric, laparoscopic cholecystectomy and the Fundamentals of Laparoscopic Surgery (FLS). Wednesday also features the SAGES Education and Research Foundation Awards Luncheon, recognizing distinguished leaders for their work in minimally invasive surgery and helped to keep patient safety and MIS in the forefront. Thursday, April 23, 2009 continues with more courses on foregut and advanced laparoscopic techniques, a special Allied Health Symposium on patient safety, a Endolumenal/NOTES® Symposium, a robotics panel, a forum and luncheon for surgical educators, and the SAGES Great Presidential Debates, a session dedicated to a broad range of issues including Universal Healthcare. Both Friday and Saturday's sessions are devoted to a range of engaging panels, concurrent sessions and keynote lectures. Dr. John Cameron will be delivering the Gerald Marks Lecture, "The Surgeon as a Role Model" on Friday with Dr. Catherine DeAngelis, Editor of JAMA, delivering the Health Policy Lecture on conflict of interest on Saturday.

SAGES Exhibits, Learning Center and Posters are open Thursday through Friday with the Poster session running until Saturday, April 25th.

Since 2005 the SAGES Scientific Session and Postgraduate Courses have been a part of Surgical Spring Week, a week of surgical meetings which have included the American College of Surgeons and the American Hepato-Pancreato Biliary Association. In 2009 SAGES meets once again with the International Pediatric Endosurgery Group (IPEG), the premiere international association for physicians who perform minimally invasive surgery in children. Several joint sessions have been incorporated into both programs including the joint panel, "Urgent and Emergent Acute Case Problems in Pediatric and Adult Patients" on Friday afternoon.

More information about the annual meeting and Surgical Spring Week is posted regularly on the SAGES website, http://www.sages.org/meetings/. Interested parties may sign up for our e-newsletter by submitting an email address on the same site.

Questions should be directed to SAGES, 11300 W. Olympic Bvld., Suite 600, Los Angeles, CA 90064, Phone: 310-437-0544, Fax: 310-437-0585, Email: sagesweb (at) sages (dot) org

# # #

Contact Information Jennifer Clark

Society of American Gastrointestinal and Endoscopic Surgeons

http://www.sages.org

310-437-0554

Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article

Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article

Stemedica provides its observations and comments to the media regarding the PLoS Medicine article published online February 17, 2009. The PLoS Medicine article describes a patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated transplants of "fetal neural stem cells" in Russia starting in 2001.

San Diego, California (PRWEB) February 27, 2009 -- Stemedica Cell Technologies (http://www.stemedica.com), Inc. ("Stemedica") provided its observations and comments to the media regarding the PLoS Medicine article published online February 17, 2009. The PLoS Medicine article describes a patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated transplants of "fetal neural stem cells" in Russia starting in 2001.

"All of us at Stemedica would like to extend our condolences to the young patient involved in this situation and our hope is for a speedy and positive outcome to this unfortunate experience. Never before have we or any of our Principal Investigators ever encountered such an occurrence either in our own research or in any of the published research", said Dr. David Howe, Stemedica's Vice President and Medical Director.

"We want to use this unfortunate incident to warn those seeking stem cell therapy abroad," warns Dr. Nikolai Tankovich, President & Chief Medical Officer of Stemedica, "to make certain that the manufacturer of the stem cells used in transplantation comply with the rigid standards that have been established by the FDA and other Internationally-recognized regulatory agencies. The future of this industry and the safety of all future patients depend on such adherence." FDA Compliance and Surveillance Standards can be referenced by visiting www.fda.gov/cber/compliance.htm (http://www.fda.gov/cber/compliance.htm).

The report in PLoS, Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient (http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.1000029), describes the development of multifocal glioneuronal neoplasms along the spinal nerves and brain stem in a 13-year-old patient who underwent repeated transplantation procedures in an attempt to treat ataxia-telangiectasia (A-T). A-T is a progressive neurodegenerative disorder known to have an increased risk of developing cancer.

Malignancy and neoplasia are common in A-T secondary to deficient cellular and humoral immunity. This immune deficiency is a contra-indication to stem cell transplant therapy. In addition, the mutations associated with A-T in the A-T mutation gene lead to mutations in nuclear protein, which normally repairs DNA. This loss of DNA repair combined with immune deficiency in A-T increases risk of neoplasia with and without cellular transplant therapy in A-T.

"Due to age, children and adolescents have significantly increased quantities of growth factors. Adding stem cells, known for their growth factor production capabilities, to a child with this presenting condition may have been a contributing factor. As in the administration of pharmaceuticals, many of which are not recommended for use in children and adolescents in the same way as in treating adults, great care must be taken in using stem cell therapy with this population of patients", said Dr. Michael Bayer, Stemedica's Director of Medical Services.

Based on the facts and references cited within the PLoS Medicine article, researchers have discovered that some of the cells were female and had two copies of the gene that causes A-T. Karyotype testing was reported in this case which confirms inadequate testing of the stem cells prior to transplantation. "The stem cell preparation protocol provided to the parents by the treatment team was reviewed and found to be inadequate by our standards", said Dr. Howe. "No cell characteristics, cell markers or bio-safety data was present. Mechanical desegregation in the 8-12 week age fetus is not recommended. Enzymatic separation is preferred, a process that also removes any dead cells that may be present. There is also a significant lack of detail on the number of cell passages as well as the dispersion of the neurospheres", Dr. Howe went on to say.

Dr. Alex Kharazi, Stemedica's Vice President for Manufacturing & Research observed, "Limited cell culturing in only 12-16 days as described in their protocol is like using a crude primary culture of cells. There are numerous risks associated with using crude cell preparations that have not been subjected to rigid manufacturing and testing protocols such as purity, identity and potency. In addition, the antibiotics used to manufacture the stem cells, are potentially neurotoxic." Dr. Kharazi went on to say, "Overall the description provided for the manufacturing protocol was vague and a poor example of what a well thought out manufacturing and safety-driven process should be. For example, there was no data provided relating to tumorgenicity, toxicity, or bio-distribution testing of the manufactured cells in nude mice which is a mandatory requirement as a first and critical step to assessing cell safety."

"Stemedica is committed to a manufacturing process that puts safety first at all times. Our stem cell product lines go through extensive testing during several stages of the manufacturing process and are also subjected to in-depth pre-clinical studies before filing with the FDA and other regulatory agencies for clinical trials", continued Dr. Kharazi. "Nothing is more important than the welfare of the patient and there is no explanation that can justify any deviance from compliance to FDA guidelines for the manufacturing and testing of stem cells prior to administration. These are the guidelines we follow and any patient considering stem cell therapy, at any location worldwide, should confirm that the manufacturer is in full compliance before they decide to undergo stem cell transplantation." warns Dr. Kharazi.

About Stemedica Technologies, Inc.

Stemedica Cell Technologies Inc. (http://www.stemedica.com (http://www.stemedica.com)) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Stemdedica complies with the standards and guidelines established by the FDA and the FDB (Food and Drug Board) in the manufacturing and testing of its stem cells. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative diseases, sight restoration and wound repair. Stemedica is based in San Diego, California.

Media Contact for Stemedica: Dave McGuigan at dmcguigan (at) stemedica.com.

###

Contact Information Dave McGuigan

Stemedica Cell Technologies Inc

http://www.stemedica.com

+1 858 658 0910

Stemedica Advances its Certification to Become a Licensed Manufacturer of Adult Stem Cells for U.S. Based Clinical Trials

Stemedica Advances its Certification to Become a Licensed Manufacturer of Adult Stem Cells for U.S. Based Clinical Trials

Stemedica Cell Technologies, Inc. announced today that it has filed with the Food and Drug Branch of the State of California's Department of Public Health for certification as a licensed manufacturer of adult stem cells for U.S.-based Phase I and Phase II Clinical Trials.

San Diego, CA (PRWEB) February 25, 2009 -- Stemedica Cell Technologies (http://www.stemedica.com), Inc. ("Stemedica") announced today that it has filed with the Food and Drug Branch of the State of California's Department of Public Health for certification as a licensed manufacturer of adult stem cells for U.S.-based Phase I and Phase II Clinical Trials. Readiness for manufacture includes obtaining a California Drug Manufacturing License for the Stemedica facility in San Diego, California.

"Completion of this certification will allow us to manufacture stem cells under contract for clinical trials for Stemedica as well as for other companies and research centers in California and across the United States. This marks a significant milestone along the journey toward the future availability of stem cell treatment for patients who so urgently need it," said Dr. Maynard Howe, Vice Chairman and CEO at Stemedica.

To prepare for inspection, Stemedica fully reconstructed its facility according to FDA requirements, which had previously focused on research and development. Stemedica's manufacturing facility now includes a fully compliant manufacturing wing with entry-level gowning rooms, two ISO class 8 sterile gowning suites, an ISO Class 7 Manufacturing Clean Room, an ISO Class 7 Processing Clean Room, a Good Manufacturing Process compliant materials warehouse and a controlled-access Quality Control testing laboratory.

"As soon as Stemedica secures its license from the State of California's Department of Public Health, we plan on filing for one or more IND's (Investigative New Drug) for specific indications with the FDA using our proprietary technology. The final major step by the Food and Drug Branch within the Department of Public Health is an in-depth, in-person inspection by their personnel. We're particularly proud of the fact that we are ready for, and capable of, seeking licensing in California, which has exceptionally stringent standards," said Dr. Alex Kharazi, Vice President, Research & Manufacturing at Stemedica.

"Becoming a Licensed Manufacturer of clinical grade adult stem cells is a significant scientific and medical step forward for the Company," said Dr. Nikolai Tankovich, Stemedica's President and Chief Medical Officer. "Securing this status will allow us to become a primary CMO (Contract Manufacturing Organization) for other for-profit companies and the many research organizations interested in advancing stem cell research through clinical application. Additionally, achieving this regulatory status within the manufacturing world will provide Stemedica with the foundation to advance its own Phase I and Phase II Clinical Studies once approved by the FDA."

About Stemedica Technologies, Inc.

Stemedica Cell Technologies Inc. (www.stemedica.com (http://www.stemedica.com)) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, California.

Media Contact for Stemedica: Dave McGuigan -- dmcguigan (at) stemedica.com.

###

Contact Information Dave McGuigan

Stemedica Cell Technologies Inc

http://www.stemedica.com

+1 858 658 0910

Dance Exercise Still The Best Way To Lose Weight Fast & Get In Shape In Tight Economy.

Dance Exercise Still The Best Way To Lose Weight Fast & Get In Shape In Tight Economy.

Many people are abandoning gym memberships and are opting to buy exercise videos to help them lose weight on a budget. Fitness expert Kenn Kihiu says despite latest fitness gimmicks, dance exercise has stood the test of time and is still the best and least expensive way to burn body fat and quickly get in shape while having fun.

Washington, DC (PRWEB) February 24, 2009 -- Exercise videos (http://www.dancexfitness.com) are now the hottest trend as family budgets continue to shrink. Sales are up 65 percent year-on-year according to Tesco. As consumers face cutbacks in the tough economy many are ditching their gym memberships and are now choosing to exercise in the comfort of their homes. Many have realized that exercise videos are cheap, convenient and can be used regardless of the weather.

One of the best selling dance exercise videos (http://www.dancexfitness.com) dominating the market is 'DanceX - Total Body Cardio.' This new exercise video features some of the best dance music from around the globe. It's also fun and very easy to follow even for those with two left feet.

The DanceX (http://www.dancexfitness.com) workout is a much welcomed and needed breath of fresh air in the current hip hop age of complicated exercise videos. The primary reason for the surge in popularity is because DanceX will meet you where are in terms of your talent and fitness ability.

Instead of making dance exercise difficult, it features fun easy to follow dance moves that are mostly low impact. DanceX is part dance, part aerobics and completely fun and not to mention a total body workout. Perfect for those who want to get fit, feel younger and have fun -- while traveling around the globe with some of the hottest music from around the world.

DanceX features the creator Kenn Kihiu a well known consumer health and fitness expert who has a dazzling smile and is choke-full of encouragement, and contagious enthusiasm. When producing this video he opted to use real people and not just fitness models who are 5'7" and 110 lbs. For example one of the background exercisers looks like your average full figured woman in her forties who seems to be having a lot of fun but also fighting to keep up with Kenn.

When it comes to losing weight and getting in shape, Kihiu is a dance exercise (http://www.dancexfitness.com) evangelist because he doesn't know of any other type of workout that can be so effective and yet be so much fun. "Consistency yields results and people will only exercise regularly and more passionately if they are having fun" Kihiu says.

Kenn's new dance exercise videos combine incredible music from around the world (Disco, Latin dance, 50's, Bhangra, Africa, Brazilian Samba, Irish Dance, Classical Music, and Soul Dance) with fun dance exercise moves everyone will love such as The Chicken, Hitch Hike, Disco Rolls, John Travolta Point, Irish Kicks, The Twist, and many others.

During the DVD's 42-minute easy-to-follow dance exercise workout, Kenn well known for his energy and sense of humor calls out the moves in advance so there is no need to memorize them. "The only requirement needed is a heartbeat!" says the charming and motivating Kenn Kihiu.

'DanceX - Everybody's Workout: Total Body Cardio.' Is only available at http://www.dancexfitness.com and retails at $24.95 with free shipping for a limited time. It also features '7 Nutrition Tips for Improving Your Health,' an "8 Minute Abs Workout, a danceX Promo Trailer, a 'Move Your Body, Move Your Life' featurette.

###

Contact Information Kenn Kihiu

301-960-4968